In Vivo Podcasts

Norstella
Norstella

In Vivo Podcasts is produced by the teams behind In Vivo, Scrip and Medtech Insight and covers biopharma and medtech in one place: the strategy, the science and the deals. Every Tuesday, Strategic Intent is a candid, long-form conversation with one senior guest, including chief executives, R&D leaders, investors and regulators. Once a month, Proof of Concept goes deep on the science, from AI-designed drug discovery to the RNA therapeutics wave. And each month Scrip's Due Diligence follows the money: the M&A, licensing and financings redrawing the industry. Hosted by a rotating line-up of editors and reporters. Stay ahead with expert insight and intelligence. Visit https://insights.citeline.com/in-vivo for daily newsletters and life sciences commercial intelligence. For any podcast feedback or queries, you can now reach us at podcasts@norstella.com.

  1. 5d ago

    Strategic Intent: Celebrity Marketing In The Age Of Promo Crackdown

    Can a celebrity campaign still work for a drug company when the FDA is watching every word? In this episode of Strategic Intent, Frank Watanabe, CEO of Arcutis Biotherapeutics, discusses the company’s latest brand awareness push and what it takes to commercialize a topical dermatology drug in an increasingly scrutinized promotional environment.​​ Commercial strategies, ad campaigns, dermatology

  2. Oct 6

    Strategic Intent: Using Agentic AI To Create ‘The Self-Driving Clinical Trial, Kind Of Like The Car’

    In this Strategic Intent episode, In Vivo speaks with Ken Getz, executive director of the Tufts CSDD and research professor at the Tufts University School of Medicine, and Pamela Tanaerts, CMO and CSO at Medable, to discuss promising data from an AI Clinical Monitoring Agent.

  3. Oct 2

    Proof of Concept - Can AI Outrun the Next Outbreak?

    What if you could design a diagnostic and a therapeutic directly from a pathogen's genetic code, faster than the disease can spread? Jared Bauer, co-founder and CEO of Seek Labs, joins Proof of Concept to explain how his company's AI engine maps conserved targets across 145+ pathogens to build programmable CRISPR therapeutics and rapid, lab-free diagnostics.

    Proof of Concept - Can AI Outrun the Next Outbreak?

  4. Oct 1

    Assessing the current dealmaking environment for psychedelic medicine.

    Joseph Haas and Emma Wille overview the dealmaking environment for psychedelic medicine given recent developments in the space: Eli Lilly's $2.8 billion acquisition of AtaiBeckley in July, the imminent FDA filing of Compass Pathways' COMP360 for treatment-resistant depression and a more relaxed regulatory environment for psychedelic therapies under the current administration.

  5. Sep 28

    Strategic Intent: Boehringer Ingelheim's Brian Hilberdink on Launching Into the GLP-1 Era

    Brian Hilberdink, President of US Human Pharma at Boehringer Ingelheim, joined Strategic Intent to talk about leading one of the company's most ambitious US launch periods in years, spanning a specialty drug in interstitial lung disease, an established franchise in cardiometabolic disease and a potential entry into the hyper-competitive obesity market. He discusses how private ownership shapes long-term decision-making, why he wants to reframe the obesity conversation away from the scale and toward metabolic health, how the payer landscape has fundamentally changed since he started in the industry, and what role AI will play in the future of commercialization.

  6. Sep 21

    Strategic Intent: Rubedo’s Seno-Adaptive Bet On Longevity Medicine

    In this episode of Strategic Intent, In Vivo senior reporter David Wild speaks with Frederick Beddingfield, CEO of Rubedo Life Sciences, about turning the biology of aging into real medicines. They discuss Rubedo’s lead topical GPX4 modulator RLS‑1496 in actinic keratosis, psoriasis, atopic dermatitis, and photo‑aged skin; a new push into androgenetic alopecia; and the company’s “seno-adaptive” approach to selectively clearing or rejuvenating aging cells. The conversation also explores Rubedo’s AI-enabled drug discovery platform, how dermatology can validate a broader longevity thesis, and what it will take for aging biology to become a credible, commercial drug category.

  7. Sep 15

    Strategic Intent: Next‑Generation Cancer Vaccines And Nouscom’s Strategy For Interception And Personalization

    Personalized and off‑the‑shelf cancer vaccines are moving from concept to clinic, raising new questions about differentiation, manufacturability, and commercial value. In this episode of Strategic Intent, In Vivo’s David Wild speaks with Marina Udier, CEO of Nouscom, about how the Basel‑based biotech is positioning its viral vector platform in this evolving landscape. They discuss NOUS‑209, an off‑the‑shelf neoantigen vaccine for MSI‑H/dMMR tumors and cancer interception in Lynch syndrome, the company’s personalized program NOUS‑PEV, and what it will take—scientifically, operationally, and commercially—for next‑generation cancer vaccines to succeed.

  8. Sep 8

    Strategic Intent: Evolving Requirements Of Life Sciences Leadership

    In this episode of Strategic Intent, Nick Stephens, chairman of the recruitment and executive placement company RSA group, looks at the state of executive leadership across the life sciences and biotech industries, reflecting on inflection points for hiring practices and emerging structural trends.

See All (26)

Trailer

About

In Vivo Podcasts is produced by the teams behind In Vivo, Scrip and Medtech Insight and covers biopharma and medtech in one place: the strategy, the science and the deals. Every Tuesday, Strategic Intent is a candid, long-form conversation with one senior guest, including chief executives, R&D leaders, investors and regulators. Once a month, Proof of Concept goes deep on the science, from AI-designed drug discovery to the RNA therapeutics wave. And each month Scrip's Due Diligence follows the money: the M&A, licensing and financings redrawing the industry. Hosted by a rotating line-up of editors and reporters. Stay ahead with expert insight and intelligence. Visit https://insights.citeline.com/in-vivo for daily newsletters and life sciences commercial intelligence. For any podcast feedback or queries, you can now reach us at podcasts@norstella.com.

Information

More From Norstella